Company Overview and News

 
Cover Story: Does Malaysia still need a national carrier?

20h theedgemarkets
IN January, Khazanah Nasional Bhd said Malaysia Airlines Bhd had until the middle of next year to be profitable. But there are signs that the airline could miss yet another deadline.
5238 JAPSY

 
Cover Story: Malaysia Airlines still not out of the woods

21h theedgemarkets
WHEN sovereign wealth fund Khazanah Nasional Bhd unveiled a turnaround plan for the country’s flagship carrier in August 2014 that saw the rebooting of Malaysian Airline System Bhd (MAS) into a leaner Malaysia Airlines Bhd, there were high hopes it would achieve success similar to that at Japan Airlines (JAL).
AL 5238 MLYAF JAPSY C6L ALLLZ BOE MYPRY SINGY BA 5014 SINGF

 
Singapore Airlines pilots not allowed to consume alcohol within 10 hours of flight

2018-09-17 channelnewsasia
SINGAPORE: Pilots with Singapore Airlines (SIA) are not allowed to consume alcohol within 10 hours from their flight duty, and there are stiff penalties set out in the Air Navigation Act if they are found to be under the influence of any psychoactive substances.
JAPSY C6L SINGY SINGF

 
Malaysia Airlines still not out of the woods

2018-09-08 theedgemarkets
When sovereign wealth fund Khazanah Nasional Bhd unveiled a turnaround plan for the country’s flagship carrier in August 2014 that saw the shut down of Malaysian Airline System Bhd and rebooted into a leaner, smaller Malaysia Airlines Bhd, there were high hopes for it to achieve similar success as Japan Airlines (JAL).
JAPSY MLYAF

 
Rescuers with dogs search for survivors after deadly Japan quake

2018-09-07 channelnewsasia
Rescue workers with dogs searched for survivors on Friday in debris-strewn landslides caused by an earthquake in Japan's northern island of Hokkaido that killed at least 16 people, officials said, with 26 still missing.
JAPSY TOPPY TM ALNPY 7203 TONPF TYT ALNPF 9202 TOYOF

 
Death toll from Japan's Hokkaido earthquake rises to 18

2018-09-07 channelnewsasia
TOKYO: The death toll from a powerful earthquake that rattled the northern Japanese island of Hokkaido doubled to at least 18, Prime Minister Shinzo Abe said on Friday (Sep 7), with more than half the island's 5.3 million residents still without power.
JAPSY TOPPY TM 7203 TONPF TYT TOYOF

 
Rescuers with dogs search for survivors after deadly Hokkaido quake

2018-09-07 channelnewsasia
Rescue workers with dogs searched for survivors on Friday in debris-strewn landslides caused by an earthquake in Japan's northern island of Hokkaido that killed at least 16 people, officials said, with 26 still missing.
JAPSY TOPPY TM 7203 TONPF TYT TOYOF

 
UPDATE 1-Rescuers with dogs search for survivors after deadly Hokkaido quake

2018-09-07 reuters
TOKYO (Reuters) - Rescue workers with dogs searched for survivors on Friday in debris-strewn landslides caused by an earthquake in Japan’s northern island of Hokkaido that killed at least 16 people, officials said, with 26 still missing.
JAPSY TOPPY TM 7203 TONPF TYT TOYOF

 
Death toll from Japan's Hokkaido earthquake rises to 16

2018-09-07 channelnewsasia
TOKYO: The death toll from a powerful earthquake that rattled the northern Japanese island of Hokkaido doubled to at least 16, Prime Minister Shinzo Abe said on Friday (Sep 7), with more than half the island's 5.3 million residents still without power.
JAPSY TOPPY TM 7203 TONPF TYT TOYOF

 
Death toll from Japan's Hokkaido doubles to 16 - prime minister

2018-09-07 channelnewsasia
The death toll from a powerful earthquake that rattled the northern Japanese island of Hokkaido doubled to at least 16, Prime Minister Shinzo Abe said on Friday, with more than half the island's 5.3 million residents still without power.
JAPSY TOPPY TM 7203 TONPF TYT TOYOF

 
Death toll from Japan's Hokkaido doubles to 16 - prime minister

2018-09-07 reuters
TOKYO (Reuters) - The death toll from a powerful earthquake that rattled the northern Japanese island of Hokkaido doubled to at least 16, Prime Minister Shinzo Abe said on Friday, with more than half the island’s 5.3 million residents still without power.
JAPSY TOPPY TM 7203 TONPF TYT TOYOF

 
Asia Markets: Asian markets mixed, though Nikkei sags again

2018-09-06 marketwatch
Asian stock markets were mixed in early trading Thursday, after a tech selloff on Wall Street.
JAPSY HYUO HYUP HYUD

107
20 Consumer Discretionary Stocks to Bolster Your Portfolio

2018-09-05 investorplace - 3
Despite a rough and tumble year in the markets, consumer discretionary stocks have surprisingly outperformed expectations. Since the beginning of January, the S&P 500 consumer discretionary index gained over 16%. In contrast, the benchmark exchange-traded fund SPDR S&P 500 ETF (NYSEARCA:SPY) has returned just over 9%.
STZ.B JAPSY UAA RCL PYPL AMD CNK UAL RGR WYND AMZN WVVI WEED AAPL DIS NCMI EBAY SMG MO FOX F AMC CMCSA STZ CGC VSTO UA SNE FOXA CAKE LIND

 
Nikkei down as typhoon damage fears hit cosmetics shares

2018-09-05 reuters
TOKYO, Sept 5 (Reuters) - Japanese shares fell on Wednesday as worries that a tariff war between China and the United States could escalate weighed on sentiment, while concerns that tourists will shop less due to a typhoon flooding a major airport hit shares in cosmetic makers.
JAPSY PORBF ALNPY ALNPF 9202 4927 LN

 
Typhoon damage fears, trade disputes, hit Japanese shares

2018-09-05 reuters
TOKYO, Sept 5 (Reuters) - Concerns about economic damage from a powerful typhoon as well as underlying caution over international trade disputes hit Japanese shares on Wednesday, putting the Nikkei index on course for a fourth consecutive day of losses.
JAPSY PORBF ALNPY ALNPF 9202 4927 LN

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 471038109